Journal of Chinese Pharmaceutical Sciences ›› 2015, Vol. 24 ›› Issue (6): 412-418.DOI: 10.5246/jcps.2015.06.053

• Original articles • Previous Articles    

The impact of obesity in managing diabetes

Xiaohui Xie1, Fei Wang2*, Jiayu Cui1   

  1. 1. Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China
    2. Department of Pharmacy Practice, University of Connecticut School of Pharmacy, Storrs, Connecticut 06269, USA
  • Received:2015-03-20 Revised:2015-05-13 Online:2015-06-26 Published:2015-05-19
  • Contact: Tel.: 1860-922-0074/1860-972-4125


The epidemic of diabetes has been fueled by a parallel increase in the prevalence of overweight and obesity. Both diabetes and overweight/obesity have become major public health problems causing increased morbidity and mortality and are important risk factors for cardiovascular disease.Cardiovascular disease is the leading cause of death in China. Excess weight has been shown to be associated with increased prevalence of type 2 diabetes, hypertension, dyslipidemia, metabolic syndrome and certain cancers; while weight loss dramatically reduces these obesity-related diseases. Overweight and obesity are important modifiable risk factors for diabetes and cardiovascular disease. There has also been encouraging progress in treatments for obesity. In 2013, the American Medical Association declared obesity a “disease state”requiring a range of medical interventions to advance obesity treatment and prevention. Since 2012, four new drugs have been approved by the U.S. FDA for the treatment of obesity.

Key words: Obesity, Type 2 diabetes mellitus, Obesity treatment, Anti-obesity drugs

CLC Number: